SARS CoV 2 News and Research

RSS

Sanford Burnham Prebys announces research agreement with Lilly to identify COVID-19 antibodies

Sanford Burnham Prebys Medical Discovery Institute today announced a research agreement with Eli Lilly and Company (Lilly) to characterize Lilly's next-generation anti-SARS-CoV-2 antibodies.

29 Jun 2020

Virus re-emergence after lockdown ends

A new report in the journal Nature Human Behaviour in June 2020 reports predictions as to the effects of removing lockdown restrictions on the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and suggests that individual responsibility concerning social distancing and other precautions could avoid the need for lockdowns.

28 Jun 2020

Similarities between coronaviruses and human genes promote infection

A new study published on the preprint server bioRxiv* in June 2020 shows that the proportion of A/T pairing in viral genomes may increase the tendency to infect humans because of the matching molecular features in some host genes, that increases the susceptibility of the host to the virus.

28 Jun 2020

Genomics used to trace origin of SARS-CoV-2 in Canada

A new study published in June 2020 on the preprint server bioRxiv discusses the use of phylogenetic analysis to trace the origin of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and its spread into and then within Canada. The study findings may help optimize public health policies in the case of future outbreaks.

28 Jun 2020

Study identifies small molecule inhibitors of SARS-CoV-2 which block key cellular kinases

Antiviral drug screen of kinase inhibitors, which was done by researchers from the University of California and Cedars-Sinai Medical Center, identified cellular signaling pathways critical for SARS-CoV-2 replication and revealed an important mechanism of host-pathogen interaction vital for further drug research. Their results are available on the bioRxiv* preprint server.

28 Jun 2020

Mathematical model reveals the risk of SARS-CoV-2 infection after fecal microbiota transplantation

In their new paper available on the bioRxiv* preprint server, US researchers from the OpenBiome nonprofit organization used a mathematical model to simulate the usefulness of different testing strategies for fecal samples and showed that the probability of releasing a fecal microbiota donation with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is low when several important variables are taken into account.

28 Jun 2020

COVID-19 patients can rapidly generate virus-attacking T cells, shows study

Patients suffering from severe respiratory symptoms as a result of SARS-CoV-2 infection can rapidly generate virus-attacking T cells, and can increase this production over time, suggests a new study of T cells from 10 COVID-19 patients under intensive care treatment.

27 Jun 2020

Brazilian startup to develop a low-cost high-performance COVID-19 diagnostic test

Researchers at Biolinker, a biotech startup based in São Paulo, Brazil, are developing a low-cost high-performance COVID-19 diagnostic test using only locally sourced inputs.

26 Jun 2020

Timing of antibody testing is critical for accurate COVID-19 detection

Scientists have analysed data from around the world to examine the accuracy of antibody tests for COVID-19, and have shown that the timing of testing is critical. The tests do not work accurately when administered at the wrong time.

26 Jun 2020

PrecisionLife scientists identify 68 genes linked to severe COVID-19 risk

PrecisionLife’s unique AI platform has found 68 genes associated with risk of developing severe COVID-19 after analysis of the genomes of 929 patients from the UK Biobank who had a severe response to SARS-CoV-2.

26 Jun 2020

Ecolab increases production capacity to meet exponential demand for hand sanitizers

In response to the pandemic, Ecolab, the global leader in water, food safety and infection prevention solutions and services, has increased its production capacity seven fold in Europe to provide customers with critical hand sanitizer and surface disinfectant solutions to help prevent the spread of SARS-CoV-2, the virus that causes COVID-19.

26 Jun 2020

Fatalities are very rare in children with COVID-19

Children with COVID-19 generally experience a mild disease and fatalities are very rare, according to a study of 582 patients from across Europe published today in The Lancet Child & Adolescent Health journal.

26 Jun 2020

Researchers perform first X-ray measurements on SARS-CoV-2 main protease

A team of researchers at the Department of Energy's Oak Ridge and Argonne national laboratories has performed the first room-temperature X-ray measurements on the SARS-CoV-2 main protease -- the enzyme that enables the virus to reproduce.

26 Jun 2020

Study shows COVID-19 infection is a risk factor for acute strokes

COVID-19 infection is significantly associated with strokes, and patients with COVID-19 should undergo more aggressive monitoring for stroke.

26 Jun 2020

Antibody tests may give false hope of immunity, health experts warn

Amid the coronavirus pandemic, health experts warn against the use of antibody tests to determine if a person has immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). An antibody test determines if a person developed antibodies against the infection due to past exposure.

26 Jun 2020

China to initiate phase 3 SARS-CoV-2 vaccine trial in UAE

Now, China is ready to run its large-scale phase III clinical trial of its novel coronavirus candidate in the United Arab Emirates (UAE). Over a dozen experimental vaccines are being trialed across the globe, but China’s vaccine is the first one to proceed to phase III human trials.

26 Jun 2020

Chilblains and COVID-19

The current COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is primarily a respiratory infection, though the majority of cases are asymptomatic or mild disease. However, other manifestations are also being reported, such as gastrointestinal features, neurological signs, and skin symptoms. A new study published online in the journal JAMA Dermatology in June 2020 examines the possibility that chilblains could be a manifestation of COVID-19.

26 Jun 2020

Genes associated with SARS-CoV-2 human lung cell infection

Now, a new study published on the preprint server bioRxiv in June 2020 attempts to make sense of this data to identify viral genes that are explicitly expressed in the cells infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This could help reveal new therapeutic targets.

26 Jun 2020

SARS-CoV-2 has been evolving for at least 7 years

The burning question is how novel viruses acquire the ability to recognize, bind to and enter human cells for the first time – whether this is dependent only on viral proteins recognizing host cell proteins, or adaptations in other viral processes that allow replication in a human host.

25 Jun 2020

Entos Pharmaceuticals selects two lead DNA vaccine candidates for COVID-19

Entos Pharmaceuticals, a healthcare biotechnology company developing nucleic acid medicines with its Fusogenix drug delivery platform, today announced the selection of two lead candidates for a pan-coronavirus Fusogenix DNA vaccine from its prototyping program launched at the onset of the global COVID-19 pandemic.

25 Jun 2020